Pharmaceuticals Global On demand · 24-48h

Global Long-Acting Reversible Contraception(LARC) Market Strategic Research Report

Global Long-Acting Reversible Contraception(LARC) Market Str…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Long-Acting Reversible Contraception(LARC) Market
$1.33B2025
6.2%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Intrauterine Devices (IUCs), Subcutaneous Implant

By Application: Age 20~24 Years Old, Age 25-34 Years Old, Age 35~44 Years Old, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Bayer, Merck, Teva Pharmaceutical, Allergan, HRA Pharma, Eurogine, Yantai Family Planning Pharmaceutical Equipment Co., Ltd., Wuxi Tianyi Medical Equipment Co., Ltd., SMB Corporation, Shenyang Liren, Tianjin Hejie Medical Equipment Co., Ltd., Cooper Companies, AbbVie Allergan, Organon, Shanghai Dahua Pharmaceutical

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 112 pages
Market size 2025
$1.33B
Billion USD
Forecast CAGR
6.2%
2025-2032
Forecast 2032
$2B
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

Overview

Scope of the Report

The global Long-Acting Reversible Contraception(LARC) market size is predicted to grow from US$ 1,326 million in 2025 to US$ 2,008 million in 2032; it is expected to grow at a CAGR of 6.2% from 2026 to 2032.

Long-acting reversible pregnancy (LARC) is a birth control method that provides long-term pregnancy prevention. LARC can provide protection for three to 10 years or more.

The global pharmaceutical market is 1,475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1,005 billion in 2018 to 1,094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Long-Acting Reversible Contraception(LARC) market?

What factors are driving Long-Acting Reversible Contraception(LARC) market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Long-Acting Reversible Contraception(LARC) market opportunities vary by end market size?

How does Long-Acting Reversible Contraception(LARC) break out by Type, by Application?

This report presents a comprehensive overview of the global Long-Acting Reversible Contraception(LARC) market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Intrauterine Devices (IUCs)
  • Subcutaneous Implant

Segment by Application

  • Age 20~24 Years Old
  • Age 25-34 Years Old
  • Age 35~44 Years Old
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Long-Acting Reversible Contraception(LARC) market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Age 20~24 Years Old, Age 25-34 Years Old, Age 35~44 Years Old evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Long-Acting Reversible Contraception(LARC) Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 6.2%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.33B
2025
Forecast
$2B
2032
CAGR
6.2%
2025–2032
Regions
5
global
Key companies
BayerMerckTeva PharmaceuticalAllerganHRA PharmaEurogineYantai Family Planning Pharmaceutical Equipment Co., Ltd.Wuxi Tianyi Medical Equipment Co., Ltd.
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Intrauterine Devices (IUCs)Subcutaneous Implant
By Application
Age 20~24 Years OldAge 25-34 Years OldAge 35~44 Years OldOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Intrauterine Devices (IUCs)
  • 3.1.3 Subcutaneous Implant
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Age 20~24 Years Old
  • 4.1.3 Age 25-34 Years Old
  • 4.1.4 Age 35~44 Years Old
  • 4.1.5 Other
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Bayer
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Merck
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Teva Pharmaceutical
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Allergan
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 HRA Pharma
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Eurogine
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Yantai Family Planning Pharmaceutical Equipment Co., Ltd.
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Wuxi Tianyi Medical Equipment Co., Ltd.
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 SMB Corporation
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Shenyang Liren
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Tianjin Hejie Medical Equipment Co., Ltd.
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Cooper Companies
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 AbbVie Allergan
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Organon
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Shanghai Dahua Pharmaceutical
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Long-Acting Reversible Contraception(LARC) market?
The global Long-Acting Reversible Contraception(LARC) market is estimated at US$ 1.33 billion in 2025 (base year) and is projected to reach US$ 2.01 billion by 2032.
What is the forecast CAGR for the Long-Acting Reversible Contraception(LARC) market?
The market is expected to grow at a CAGR of 6.2% from 2026 to 2032, expanding from US$ 1.33 billion in 2025 to US$ 2.01 billion in 2032, roughly 1.5 times its base-year value.
What is Long-Acting Reversible Contraception(LARC)?
Long-acting reversible pregnancy (LARC) is a birth control method that provides long-term pregnancy prevention. LARC can provide protection for three to 10 years or more.
How is the Long-Acting Reversible Contraception(LARC) market segmented by type?
By type, the market is segmented into Intrauterine Devices (IUCs) and Subcutaneous Implant.
What are the key applications of Long-Acting Reversible Contraception(LARC)?
Key applications covered include Age 20~24 Years Old, Age 25-34 Years Old, Age 35~44 Years Old and Other.
Which companies are profiled in the Long-Acting Reversible Contraception(LARC) market report?
Key players profiled include Bayer, Merck, Teva Pharmaceutical, Allergan, HRA Pharma, Eurogine, Yantai Family Planning Pharmaceutical Equipment Co. and Wuxi Tianyi Medical Equipment Co., among 15 companies covered in total.
What geographies does the Long-Acting Reversible Contraception(LARC) market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Long-Acting Reversible Contraception(LARC)?
What factors are driving Long-Acting Reversible Contraception(LARC) market growth, globally and by region?
What are the main risks and barriers in the Long-Acting Reversible Contraception(LARC) market?
However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations.
Who should buy the Long-Acting Reversible Contraception(LARC) market report?
The report is intended for manufacturers and solution providers, distributors and end users in Age 20~24 Years Old, Age 25-34 Years Old and Age 35~44 Years Old, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Long-Acting Reversible Contraception(LARC) market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.